169 related articles for article (PubMed ID: 29556485)
1. Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade.
Nagai T; Naiki T; Iida K; Etani T; Ando R; Hamamoto S; Sugiyama Y; Akita H; Kubota H; Hashimoto Y; Kawai N; Yasui T
Prostate Int; 2018 Mar; 6(1):18-23. PubMed ID: 29556485
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
[No Abstract] [Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors.
Fan L; Dong B; Chi C; Wang Y; Gong Y; Sha J; Pan J; Shangguan X; Huang Y; Zhou L; Xue W
BMC Urol; 2018 Dec; 18(1):110. PubMed ID: 30509237
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Iguchi T; Tamada S; Kato M; Yasuda S; Otoshi T; Hamada K; Yamasaki T; Nakatani T
Int J Clin Oncol; 2019 Jul; 24(7):848-856. PubMed ID: 30741370
[TBL] [Abstract][Full Text] [Related]
9. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
10. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
12. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
Mori K; Kimura T; Onuma H; Kimura S; Yamamoto T; Sasaki H; Miki J; Miki K; Egawa S
Prostate; 2017 Jul; 77(10):1144-1150. PubMed ID: 28557065
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
[TBL] [Abstract][Full Text] [Related]
14. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
[TBL] [Abstract][Full Text] [Related]
15. Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.
Hiroshige T; Eguchi Y; Yoshizumi O; Chikui K; Kumagai H; Kawaguchi Y; Onishi R; Hayashi T; Watanabe K; Mitani T; Saito K; Igawa T
Oncol Lett; 2018 May; 15(5):6806-6814. PubMed ID: 29725416
[TBL] [Abstract][Full Text] [Related]
16. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Ueda Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Clin Genitourin Cancer; 2017 Apr; 15(2):320-325. PubMed ID: 27601278
[TBL] [Abstract][Full Text] [Related]
20. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]